Fintel on MSN14h
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation
Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...
Blueprint Medicines initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...